ACTR-22. RESULTS OF PHASE I OF THE PARADIGM TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH SHORT COURSE RADIOTHERAPY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

BACKGROUND: Olaparib, a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), has radiosensitising properties in pre-clinical GBM models. Because radiopotentiation is observed only in proliferating cells, we hypothesised that olaparib would enhance tumour control without exacerbating norma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Chalmers, Anthony, Stobo, Jon, Short, Susan C, Herbert, Christopher, Saran, Frank, Morris, Anna, Dillon, Susan, Kelly, Caroline
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691879/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.017
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars